Apogee Therapeutics, Inc. to Post Q1 2025 Earnings of ($0.63) Per Share, Wedbush Forecasts (NASDAQ:APGE)

Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) - Equities researchers at Wedbush issued their Q1 2025 EPS estimates for Apogee Therapeutics in a note issued to investors on Monday, May 13th. Wedbush analyst D. Nierengarten expects that the company will post earnings of ($0.63) per share for the quarter. Wedbush has a "Outperform" rating and a $87.00 price objective on the stock. The consensus estimate for Apogee Therapeutics' current full-year earnings is ($2.67) per share. Wedbush also issued estimates for Apogee Therapeutics' Q2 2025 earnings at ($0.64) EPS, Q3 2025 earnings at ($0.65) EPS and Q4 2025 earnings at ($0.67) EPS.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last issued its earnings results on Tuesday, March 5th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.13.

Other analysts have also issued reports about the company. Guggenheim boosted their price objective on Apogee Therapeutics from $44.00 to $91.00 and gave the company a "buy" rating in a report on Tuesday, March 5th. Stifel Nicolaus boosted their target price on shares of Apogee Therapeutics from $46.00 to $95.00 and gave the company a "buy" rating in a research note on Tuesday, March 5th. Jefferies Financial Group raised their price target on shares of Apogee Therapeutics from $37.00 to $75.00 and gave the stock a "buy" rating in a research report on Wednesday, March 6th. Finally, Bank of America began coverage on shares of Apogee Therapeutics in a research note on Friday. They set a "buy" rating and a $80.00 price objective on the stock. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of "Buy" and an average target price of $73.00.

Apogee Therapeutics Stock Performance

APGE stock traded up $1.27 during trading on Tuesday, reaching $54.00. The stock had a trading volume of 1,776,538 shares, compared to its average volume of 585,568. The firm has a fifty day moving average price of $57.94 and a 200 day moving average price of $38.33. Apogee Therapeutics has a 1-year low of $14.19 and a 1-year high of $72.29.

Institutional Trading of Apogee Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. EntryPoint Capital LLC increased its stake in Apogee Therapeutics by 44.7% during the 1st quarter. EntryPoint Capital LLC now owns 1,997 shares of the company's stock valued at $133,000 after buying an additional 617 shares during the period. Amalgamated Bank acquired a new stake in shares of Apogee Therapeutics in the third quarter valued at $52,000. Strs Ohio bought a new position in Apogee Therapeutics during the third quarter valued at about $87,000. Ameritas Investment Partners Inc. raised its position in Apogee Therapeutics by 111.2% in the first quarter. Ameritas Investment Partners Inc. now owns 4,126 shares of the company's stock worth $274,000 after acquiring an additional 2,172 shares in the last quarter. Finally, New York State Common Retirement Fund acquired a new stake in Apogee Therapeutics in the 3rd quarter valued at about $90,000. Institutional investors own 79.04% of the company's stock.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.